Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Decitabine and Cedazuridine + Defactinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Decitabine and Cedazuridine | Inqovi | ASTX-727|ASTX 727|ASTX727 | Chemotherapy - Antimetabolite 14 | Inqovi (decitabine and cedazuridine) is a combination of decitabine and cedazuridine, which may inhibit proliferation of tumor cells (PMID: 30926081). Inqovi (decitabine and cedazuridine) is an FDA approved chemotherapy agent (FDA.gov). |
Defactinib | VS-6063|PF-04554878 | FAK inhibitor 15 | Defactinib (VS-6063) inhibits FAK, resulting in decreased downstream signaling, and potentially leading to reduced tumor cell proliferation and survival (PMID: 31739184). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05636514 | Phase I | Decitabine and Cedazuridine + Defactinib | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS) | Recruiting | AUS | 0 |